Genetic testing could improve cancer outcomes for patients, but historical research abuses and access issues have slowed ...

The UK regulator is creating a new framework for how it will approve rare disease treatments, which it intends to publish in ...

The agency is establishing a network of care centers to expand access to regenerative medicine beyond regions served by major ...

Intellia had already paused dosing in trials of nex-z in transthyretin amyloidosis after the patient was hospitalized due to a serious adverse event.

The firm had decreased Q3 sales for precision oncology drugs including Ibrance, Tukysa, and Bosulif, but sales increased for ...

Researchers presented new data on Phenomix Sciences' genetic risk scores at the Obesity Society's ObesityWeek conference.

The firm recorded $58 million in sales for the autologous TIL therapy, which it is working on moving into earlier melanoma settings and other tumor types.

The agency said the move could halve the time it takes for biosimilars to enter the market, drive competition, and reduce ...

The hospital system is betting the move will give it better control over turnaround time and allow it to be more "nimble" in ...

The company's outlook for the rest of the year was rosier than in the previous quarter, when it announced a cost-cutting plan ...